Clinical trial · Observational
Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
NCT04920513CI-TRIAL-00087420completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aim to study the pattern and frequency of pathogenic variants among ALL newly diagnosed cancer patients in a genetically distinct population. Additionally, the investigators will study the uptake rate of "cascade family screening", frequency of pathogenic variants and barriers against testing.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Genetic Predisposition | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Prevalence of pathogenic or likely pathogenic germline variants among newly diagnosed cancer patients tested by universal multigene panel testing
- timeFrame
- 2021-2023
- measure
- Number of participants with variants of uncertain significance (VUS) as assessed by universal multigene panel testing
- timeFrame
- 2021-2023
- measure
- To determine the reasons/ Barriers for refusal of genetic cascade testing among newly diagnosed cancer patients.
- timeFrame
- 2021-2023
Secondary outcomes (4)
- measure
- Rate of cascade of family member testing of the participants with positive pathogenic mutation
- timeFrame
- 2021-2023
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patient, age ≥ 18 years at time of cancer diagnosis * Pathology proven diagnosis of cancer; any site, any stage (prior history of cancer is allowed) * Jordanian nationality * Willingness to participate * Signed consent form Exclusion Criteria: * Major psychiatric disorder (defined as: patients followed by a psychiatrist and on antipsychotic medications) * Non-Jordanian * Patients with Leukemia, Lymphoma and Myeloma
References
Publications (0)
Data not yet available
No reference posted for this study.